Gavi, the Vaccine Alliance, is an international organisation dedicated to saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.
Gavi, the Vaccine Alliance helps vaccinate almost half the world’s children against deadly and debilitating infectious diseases. Created in 2000, Gavi is an international organisation – a global Vaccine Alliance, bringing together public and private sectors with the shared goal of saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.
As a public-private partnership, Gavi represents the sum of its partners' individual strengths, from WHOs scientific expertise and UNICEF’s procurement system to the financial know-how of the World Bank and the market knowledge of the vaccine industry.
By bringing the key stakeholders in global immunisation together around one mission, Gavi combines the technical expertise of the development community with the business know-how of the private sector.
Gavi and COVID-19
In the fight against the COVID-19 pandemic, Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines. Within the COVAX Facility, Gavi established the COVID-19 Vaccines Advance Market Commitment (COVAX AMC), the innovative financing instrument that will support the participation of 92 low- and middle-income economies in the COVAX Facility – enabling access to donor-funded doses of safe and effective COVID-19 vaccines.
In June 2019, the Gavi Board approved a new five-year strategy for the 2021-2025 period. “Gavi 5.0” was established with a vision of “leaving no one behind with immunisation” and a mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines. Leveraging donor financing, empowering countries and shaping sustainable markets will help achieve the Alliance’s goals and see lower-income countries immunise an additional 300 million children by 2025, averting 7 to 8 million deaths.
IFFIm funding supports Gavi 5.0, which stresses extending the availability of vaccines despite the severe disruptions caused by COVID-19.
Building on successes of the previous strategic periods, Gavi 5.0 has several key shifts to deliver on its mission, including:
- A core focus on reaching ten million “zero-dose” children a year who have not had basic vaccines
- More differentiated, tailored and targeted approaches for Gavi-eligible countries
- An increased focus on programmatic sustainability
- Providing limited and catalytic support for select former and never Gavi-eligible countries.